Freedom to Operate (FTO) Netherlands 2026: Patent Clearance for Chemical & Biotech Launches

Freedom to operate netherlands has become one of the most pressing pre-launch questions for chemical, food-tech and industrial-biotech companies bringing new products into the Dutch and wider European market in 2026. Two forces are driving that urgency: incremental modernisation of the Dutch Octrooiwet 1995 (the Dutch Patent Act) and the now operational Unified Patent Court (UPC), which can issue cross-border injunctions that reach far beyond the Netherlands. For in-house counsel and R&D leaders, this means a national clearance mindset is no longer sufficient, a launch decision must weigh both Dutch statutory rules and pan-European enforcement exposure.

This guide sets out a practical, NL-specific FTO workflow: how to search, how to chart claims for chemical and biotech inventions, how the Bolar exemption shapes pre-launch testing, and how to manage UPC injunction risk. The aim is to give commercial teams a defensible, repeatable process that supports a confident go-to-market decision.

What is an FTO analysis and how does it differ from patentability?

A freedom to operate analysis answers a single commercial question: can you make, use, sell, offer or import your product or process in a given territory without infringing patent rights that are currently in force? It is a risk assessment focused on enforceable third-party rights, granted patents and, in some cases, pending applications that may grant. Crucially, it does not concern whether your own invention is new or inventive.

Patentability is the opposite question. It asks whether an invention is novel, involves an inventive step and is capable of industrial application, the tests a patent office applies when deciding whether to grant a patent. You can hold a perfectly valid, granted patent on an improvement and still infringe a broader, earlier patent when you commercialise it. Owning intellectual property and being free to use it in the market are two entirely separate matters, and confusing them is one of the most common and costly errors in pre-launch planning.

Example: claim scope versus patentability test

Imagine a chemical company develops a new catalytic process that improves the yield of a specialty polymer. The process may be genuinely novel and inventive, patentable in its own right. But if an earlier granted patent claims “a process for producing polymer X using a transition-metal catalyst,” and the new process falls within the literal or equivalent scope of that claim, the improvement infringes. Patentability confirms the invention is protectable; freedom to operate netherlands analysis confirms whether launching it will trigger someone else’s exclusive rights. Both are needed, and they answer different questions at different stages of product development.

FTO search and analysis in the Netherlands, a step-by-step workflow

A robust FTO analysis netherlands follows a disciplined sequence: define the product and process precisely, search the relevant patent literature, chart the closest claims against your product, and convert that technical mapping into a legal opinion with a graded risk assessment. Rushing any stage undermines the reliability of the conclusion. Below is the workflow we recommend for chemical and biotech launches.

Databases and search tools

Effective patent clearance netherlands starts with authoritative search sources. The core tools are:

• Espacenet (EPO). The European Patent Office’s free database covering a very large corpus of patent documents worldwide, with strong classification and family-linking functionality. The EPO’s official searching resources describe how to use classification codes, keyword and citation searching effectively.
• European Patent Register. For any European patent or application of interest, the Register provides legal status, opposition history, designated states and, importantly for 2026, whether the patent has unitary effect or has been opted out of the UPC.
• Netherlands national registers. Octrooicentrum Nederland, part of the Rijksdienst voor Ondernemend Nederland (RVO), maintains the Dutch national register and provides practical guidance on national patents and their status.
• Google Patents and commercial platforms. Useful for rapid full-text and semantic searching across jurisdictions and languages, and for building an initial landscape before a more forensic search.

A sound freedom to operate search eu strategy combines classification-based searching (to catch documents whether or not they use your terminology) with keyword and chemical-structure searching. For chemical inventions, structure and Markush searching in specialist databases is often essential because relevant claims may be drafted in generic terms that keyword searches miss. For biotech, sequence searching and functional-language claims demand a broader net than a purely lexical search would cast.

Claim charting best practices for chemical and biotech

Claim charting is the analytical heart of any FTO exercise. The method is to take each independent claim of a potentially blocking patent, break it into its individual features (or “limitations”), and map each feature against the corresponding element of your product or process. Infringement of a claim generally requires that every feature of that claim be present in your product, literally or under the doctrine of equivalents. If even one feature is absent, that claim is not literally infringed.

For chemical patents netherlands, charting requires particular care with:

• Markush and genus claims. A single claim may cover a vast family of compounds through generic substituent definitions. Charting must establish whether your specific compound falls within the defined genus.
• Product-by-process and process claims. A process claim is infringed only by carrying out the claimed process; a product claim can be infringed by the product regardless of how it was made. Distinguishing the two changes both the infringement analysis and the design-around options.
• Ranges and parameters. Temperature, pressure, concentration and purity ranges must be compared precisely, since operating outside a claimed range can be a legitimate route to non-infringement.

For biotech patents netherlands, the same rigour applies to sequence identity thresholds, functional definitions of proteins or antibodies, and claims to methods of production. The EPO’s guidelines on claim interpretation are a useful reference for how granted claims are construed, and Dutch courts and the UPC interpret claims in light of the description and drawings, consistent with the Protocol on the Interpretation of Article 69 EPC. A claim chart should record, feature by feature, whether an element is present, absent or arguable, the arguable cells are where legal judgement and, potentially, design-around opportunities lie.

Patent landscaping and freedom to operate search scope

Before a forensic FTO search, many companies commission patent landscaping netherlands to map the broader competitive and patent environment. Landscaping identifies the key patent holders in a technology area, reveals white space, and flags applications worth monitoring as they progress through prosecution. It is a strategic input rather than a clearance opinion, but it sharpens the scope of the subsequent FTO search.

Scoping decisions determine cost and reliability. Two questions matter most. First, territory: because a granted European patent can now take unitary effect across participating UPC states, a freedom to operate search eu must extend beyond the Netherlands to the full footprint of your intended commercialisation. Second, product versus process: you must clear both the product you sell and the process by which you make it, since either can be independently protected. A launch cleared for the product but not the manufacturing route remains exposed. Establishing scope in writing at the outset prevents disputes later about what the opinion did and did not cover.

Legal opinion, risk grading and deliverables for a launch

The output of an FTO exercise is a legal opinion, not a search report. A search report lists documents; an opinion applies legal analysis to reach a defensible conclusion about infringement risk. For a commercial launch, a well-constructed FTO opinion should contain:

• A clear statement of scope. The product/process assessed, the territories covered, the databases and date of the search, and any express exclusions.
• Identified patents of concern. The granted rights and relevant pending applications that could block the launch, with legal status confirmed.
• Claim charts. Feature-by-feature mapping for each patent of concern, showing where infringement is clear, arguable or avoided.
• A risk matrix. A graded assessment translating the legal analysis into commercial risk categories.
• Suggested design-arounds. Where a high-risk claim is identified, practical modifications to the product or process that would move it outside the claim scope.
• Limitations and assumptions. Honest statement of what the opinion does not and cannot guarantee.

Sample risk grading matrix

No FTO opinion can guarantee that no court will ever find infringement, claim construction, the doctrine of equivalents and patent validity all involve judgement. This is why the opinion should recommend mitigations proportionate to the risk grade, and why many companies pair a medium or high-risk launch with contractual indemnities from suppliers or with specialist patent-infringement insurance. Timing matters too: a reliable opinion for a complex chemical or biotech launch typically requires several weeks of searching and analysis, so counsel should be engaged well before the commercial commitment date.

Bolar exemption Netherlands, what R&D and testing is allowed pre-launch?

The Bolar exemption is a limited carve-out from patent infringement that allows certain acts otherwise reserved to the patent holder to be performed for regulatory purposes. Its origin lies in EU pharmaceutical legislation, which permits studies and trials necessary to obtain marketing authorisation for medicinal products, and it is reflected in Dutch national law under the Octrooiwet 1995. The practical effect is that a company can conduct the regulatory work needed to prepare a market-authorisation dossier without waiting for the relevant patent to expire.

For companies in the chemical, food-tech and industrial-biotech space, the scope and limits of the bolar exemption netherlands must be assessed carefully, because the exemption is targeted at acts connected to regulatory approval rather than general commercial preparation. Key points to understand:

• The exemption is purpose-bound. It covers acts done to generate data for a marketing authorisation or equivalent regulatory approval. Acts for pure commercial stockpiling or general market preparation fall outside it.
• Experimental use is distinct. Separately from Bolar, patent law generally permits acts done for experimental purposes relating to the subject matter of the invention. The interaction between the experimental-use defence and the Bolar exemption should be analysed for each specific activity.
• Product type governs applicability. Where a product does not require a medicinal or similar regulatory authorisation, the Bolar exemption may have limited or no application, and pre-launch testing may need to rely on the experimental-use defence instead.

In practice, bioassays, stability testing and analytical characterisation carried out to support a regulatory submission will often fall within the exemption where the product is subject to authorisation, whereas building commercial inventory ahead of launch will not. Because the precise boundaries turn on the purpose of each act and on evolving interpretation of the EU instruments by the Court of Justice of the European Union, the safest approach is to document the regulatory purpose of each pre-launch activity and to seek counsel confirmation for borderline testing. The interplay with supplementary protection certificates and other regulatory exclusivities, governed at EU level, adds a further layer that should be checked before relying on any exemption to shorten a launch timeline.

UPC and injunction risk, how the Unified Patent Court changes freedom to operate netherlands strategy

One of the largest changes to FTO strategy in recent years is the operation of the Unified Patent Court, which opened its doors on 1 June 2023. The UPC has jurisdiction over European patents with unitary effect and, unless opted out during the transitional period, over classical European patents across the participating member states. This transforms enforcement risk: a single action before the UPC can result in an injunction with effect across many EU markets at once, rather than country by country.

For a Netherlands launch, the implication is direct. Even where your product is aimed primarily at the Dutch market, a patent holder can bring a UPC action that, if successful, blocks sales across the participating states in which the patent has effect, and can seek a preliminary injunction to do so quickly. This raises the stakes of any medium or high-risk finding and makes a purely national clearance dangerously incomplete. A freedom to operate netherlands review in 2026 must therefore be built on a pan-EU search and a UPC-aware risk assessment.

UPC preliminary injunction risk and tactical mitigation

The UPC’s procedural framework enables comparatively fast provisional relief, which can force a defendant into difficult decisions before the merits are fully tested. Because the court’s rules emphasise expedition and centralised handling, a patent holder may obtain provisional measures that halt a launch across multiple markets while proceedings continue. That speed is precisely why upc injunction risk should be assessed at the FTO stage, not after a claim letter arrives.

Practical mitigation strategies include:

• Forum and opt-out analysis. Check the European Patent Register to see whether blocking patents have been opted out of the UPC. Opt-out status changes where enforcement can occur and shapes the risk profile.
• Design-around before launch. The most durable mitigation is to move the product or process outside the scope of the highest-risk claims, verified by an updated claim chart.
• Declaratory relief. Where appropriate, a pre-emptive declaration of non-infringement or a validity challenge can shift the initiative and reduce the surprise of an injunction application.
• Readiness for a validity attack. Assembling prior art and validity arguments in advance means a defendant can respond credibly and quickly if provisional measures are sought.

UPC versus Dutch national court: key differences for FTO risk

The national Dutch courts remain highly relevant, Dutch patent litigation has a long-standing reputation for expertise and efficiency, and Dutch court decisions are searchable through the official Rechtspraak portal. But the strategic centre of gravity for cross-border chemical and biotech launches has shifted, and FTO planning must now hold both tracks in view.

Practical checklist for a Netherlands and EU launch, timeline and counsel model

A disciplined timeline turns FTO from a last-minute scramble into a managed workstream. The following sequence works well for a launch around six months out, compressible to a shorter timeframe where necessary but with reduced comfort:

1. Months 6–5: scope and landscape. Define the product and process precisely, agree territories, and commission patent landscaping to identify the key rights and any pending applications to monitor.
2. Months 5–4: forensic FTO search. Run structure, sequence, classification and keyword searches across Espacenet, the European Patent Register and national registers, extended to the full EU footprint.
3. Months 4–3: claim charting and opinion. Chart the closest claims feature by feature, obtain a written legal opinion with a graded risk matrix, and identify design-arounds for any high-risk claims.
4. Months 3–2: mitigation and clearance testing. Implement design-arounds, complete any Bolar-permitted regulatory testing, and open licence discussions where a medium or high risk cannot be engineered away.
5. Months 2–1: risk transfer and approvals. Put supplier indemnities and, where warranted, patent-infringement insurance in place; finalise UPC opt-out and forum analysis.
6. Launch month: final refresh and go/no-go. Refresh the search for any newly granted patents, confirm the opinion still holds, and record the launch decision with its supporting analysis.

Engaging counsel at the scoping stage rather than after commitment is the single highest-value decision, because early advice shapes the product design itself and preserves the option of a low-cost design-around before manufacturing tooling and marketing spend lock in the technical choices.

Worked examples, chemical and biotech

Chemical process claim

Consider a specialty chemicals manufacturer planning to launch a coating produced by a continuous-flow process. An FTO search might identify a granted European patent claiming a continuous process for the same coating class “at a reaction temperature of 80–120°C.” A claim chart could show every feature present except the temperature range, where the company’s process runs at 65°C. Because the temperature limitation is a required feature and is not met, literal infringement would be avoided, and an equivalents analysis might conclude the lower-temperature route is not an obvious variant. On that basis a launch could proceed at low risk, with a documented instruction to operations to hold the reaction below the claimed range.

Biotech product and process

Consider an industrial-biotech company preparing an enzyme product that faces a granted claim to a protein defined by a sequence-identity threshold and a functional activity. Charting might show the company’s enzyme falling above the identity threshold, a clear infringement concern graded high. A sound remediation could combine two steps: a validity review to test whether prior art undermines the broad functional claim, and parallel licence discussions with the patent holder. Regulatory characterisation studies needed for the launch would be structured to fall within permitted testing pending resolution. The prudent course is to defer full commercial launch until the risk is resolved, avoiding premature exposure to a UPC injunction.

Conclusion

Freedom to operate netherlands in 2026 is no longer a box-ticking exercise confined to a national register. The combination of the Dutch Octrooiwet 1995 and an operational Unified Patent Court means that clearance decisions for chemical and biotech launches must integrate rigorous searching, disciplined claim charting, a properly reasoned legal opinion, careful handling of the Bolar exemption, and a UPC-aware assessment of cross-border injunction risk. The reward for doing this well is a defensible, documented launch decision that protects the commercial investment and reduces the chance of a market-halting injunction.

Companies planning a Netherlands or EU launch should engage specialist patent counsel early, scope the analysis to the full commercial footprint, and treat FTO as a strategic input to product design rather than a final formality. A structured freedom to operate netherlands review, tailored to chemical and biotech claim scope, is the foundation of a confident go-to-market decision.

Sources

1. Octrooiwet 1995 (Dutch Patent Act), wetten.overheid.nl
2. Unified Patent Court (official site)
3. European Patent Office, Searching for patents / Espacenet
4. Rijksdienst voor Ondernemend Nederland, Octrooicentrum Nederland (RVO)
5. EUR-Lex, Regulation (EC) No 469/2009 (SPC)
6. CURIA, Court of Justice of the European Union case law portal
7. Rechtspraak.nl, Dutch court decisions
8. EPO Guidelines for Examination, claim interpretation